Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2

Status

Completed 3Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 4OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1Sarcoma 1Head & Neck 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 51Small Cell Lung Carcinoma 23Breast Neoplasms 18Sarcoma 16Lung Neoplasms 10Carcinoma, Hepatocellular 10Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Neoplasms 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 7Thyroid Neoplasms 6Neoplasm Metastasis 6Esophageal Neoplasms 6Pancreatic Neoplasms 5NSCLC 5Colorectal Neoplasms 5Carcinoma 5Uterine Cervical Neoplasms 4Pheochromocytoma 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Non-squamous Non-small Cell Lung Cancer 3Glioma 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3

Interventions

pembrolizumab 156Gemcitabine 140Capecitabine 123Paclitaxel 120Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Leucovorin 97Docetaxel 97Cisplatin 89Radiosurgery 88Irinotecan 87Carboplatin 85Cetuximab 72Cyclophosphamide 71Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Neoplasm Metastasis × anlotinib × Clear all
NCT07581821 2026-05-12

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Recruiting
33 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT07562581 2026-05-01

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2 Not yet recruiting
48 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04770688 2024-08-15

AUTOMAN

Shanghai Chest Hospital

Phase 1/2 Completed
25 enrolled
Thoracic

Adenocarcinoma of Lung, Neoplasm Metastasis

NCT04860700 2024-06-12

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Peking Union Medical College Hospital

Phase 2 Completed
27 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Henan Cancer Hospital

Phase 2 Completed
42 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03416517 2019-02-15

Anlotinib and Irinotecan for Ewing Sarcoma

Peking University People's Hospital

Phase 1/2 Unknown
47 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡